# Reply to “Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach”

## TL;DR

This paper addresses feedback on a study about the cost-effectiveness of immunotherapy combinations for advanced lung cancer.

## Contribution

The authors respond to specific critiques and clarify their modeling approach and assumptions.

## Key findings

- The authors address concerns about the proportional hazard assumption in their model.
- They explain their use of the accelerated failure time model for survival analysis.
- Clarifications are provided regarding health utility estimates used in the cost-effectiveness analysis.

## Abstract

In this article, we read with great attention the correspondence by Bullement et al., regarding our published study on cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer. We referred to a few the most important comments from Bullement et al. in our opinion, including proportional hazard (PH) assumption, accelerated failure time (AFT) model, and health utility, and made some explanations.